

Holger Moch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6217180/publications.pdf>

Version: 2024-02-01

294
papers

35,941
citations

8181

76
h-index

3650

180
g-index

309
all docs

309
docs citations

309
times ranked

49250
citing authors

#	ARTICLE	IF	CITATIONS
1	Endothelial cell infection and endotheliitis in COVID-19. <i>Lancet, The</i> , 2020, 395, 1417-1418.	13.7	5,100
2	The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organsâ€”Part A: Renal, Penile, and Testicular Tumours. <i>European Urology</i> , 2016, 70, 93-105.	1.9	2,211
3	Metastatic patterns of prostate cancer: An autopsy study of 1,589 patients. <i>Human Pathology</i> , 2000, 31, 578-583.	2.0	1,483
4	Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. <i>Nature Genetics</i> , 1997, 16, 68-73.	21.4	1,461
5	The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organsâ€”Part B: Prostate and Bladder Tumours. <i>European Urology</i> , 2016, 70, 106-119.	1.9	1,323
6	Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. <i>Nature Genetics</i> , 2012, 44, 685-689.	21.4	1,300
7	The Heidelberg classification of renal cell tumours. <i>Journal of Pathology</i> , 1997, 183, 131-133.	4.5	1,142
8	The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1469-1489.	3.7	922
9	Chemokine receptor CXCR4 downregulated by von Hippelâ€™Lindau tumour suppressor pVHL. <i>Nature</i> , 2003, 425, 307-311.	27.8	845
10	An Immune Atlas of Clear Cell Renal Cell Carcinoma. <i>Cell</i> , 2017, 169, 736-749.e18.	28.9	751
11	A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. <i>Modern Pathology</i> , 2018, 31, 1770-1786.	5.5	739
12	The International Society of Urological Pathology (ISUP) Grading System for Renal Cell Carcinoma and Other Prognostic Parameters. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1490-1504.	3.7	639
13	The single-cell pathology landscape of breast cancer. <i>Nature</i> , 2020, 578, 615-620.	27.8	582
14	Metabolic Activation of Intrahepatic CD8+ T Cells and NKT Cells Causes Nonalcoholic Steatohepatitis and Liver Cancer via Cross-Talk with Hepatocytes. <i>Cancer Cell</i> , 2014, 26, 549-564.	16.8	531
15	Sarcomatoid Differentiation in Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2001, 25, 275-284.	3.7	467
16	Spectrum of Epithelial Neoplasms in End-Stage Renal Disease. <i>American Journal of Surgical Pathology</i> , 2006, 30, 141-153.	3.7	431
17	Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma. <i>Cancer</i> , 2000, 89, 604-614.	4.1	424
18	Xp11 Translocation Renal Cell Carcinoma in Adults: Expanded Clinical, Pathologic, and Genetic Spectrum. <i>American Journal of Surgical Pathology</i> , 2007, 31, 1149-1160.	3.7	381

#	ARTICLE	IF	CITATIONS
19	High-Throughput Tissue Microarray Analysis to Evaluate Genes Uncovered by cDNA Microarray Screening in Renal Cell Carcinoma. <i>American Journal of Pathology</i> , 1999, 154, 981-986.	3.8	376
20	Patterns of Gene Expression and Copy-Number Alterations in von-Hippel Lindau Disease-Associated and Sporadic Clear Cell Carcinoma of the Kidney. <i>Cancer Research</i> , 2009, 69, 4674-4681.	0.9	370
21	Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies. <i>Journal of Pathology</i> , 2001, 195, 72-79.	4.5	355
22	Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. <i>Journal of Pathology</i> , 2001, 194, 349-357.	4.5	274
23	The landscape of viral associations in human cancers. <i>Nature Genetics</i> , 2020, 52, 320-330.	21.4	261
24	Morphologic and Molecular Characterization of Renal Cell Carcinoma in Children and Young Adults. <i>American Journal of Surgical Pathology</i> , 2004, 28, 1117-1132.	3.7	253
25	Intratumor Heterogeneity in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2015, 21, 1951-1961.	7.0	251
26	Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer. <i>European Urology</i> , 2016, 69, 646-657.	1.9	249
27	Prognostic Significance of Epithelial-Mesenchymal and Mesenchymal-Epithelial Transition Protein Expression in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 7430-7437.	7.0	244
28	Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma. <i>Cancer Research</i> , 2018, 78, 1308-1320.	0.9	238
29	Two distinct immunopathological profiles in autopsy lungs of COVID-19. <i>Nature Communications</i> , 2020, 11, 5086.	12.8	230
30	Reliable detection of subclonal single-nucleotide variants in tumour cell populations. <i>Nature Communications</i> , 2012, 3, 811.	12.8	227
31	pVHL and GSK3 β are components of a primary cilium-maintenance signalling network. <i>Nature Cell Biology</i> , 2007, 9, 588-595.	10.3	220
32	Chromophobe Renal Cell Carcinoma: Histomorphologic Characteristics and Evaluation of Conventional Pathologic Prognostic Parameters in 145 Cases. <i>American Journal of Surgical Pathology</i> , 2008, 32, 1822-1834.	3.7	215
33	Periostin expression and epithelial-mesenchymal transition in cancer: a review and an update. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2011, 459, 465-475.	2.8	213
34	The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours. <i>European Urology</i> , 2022, 82, 458-468.	1.9	212
35	Chromosomal Imbalances in Papillary Renal Cell Carcinoma. <i>American Journal of Pathology</i> , 1998, 153, 1467-1473.	3.8	208
36	VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. <i>Journal of Pathology</i> , 2002, 196, 186-193.	4.5	204

#	ARTICLE	IF	CITATIONS
37	Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer. <i>Science</i> , 2014, 346, 85-89.	12.6	200
38	Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer. <i>Oncolmmunology</i> , 2018, 7, e1378844.	4.6	179
39	A Clearer View of the Molecular Complexity of Clear Cell Renal Cell Carcinoma. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2015, 10, 263-289.	22.4	175
40	Ki67 LABELLING INDEX: AN INDEPENDENT PREDICTOR OF PROGRESSION IN PROSTATE CANCER TREATED BY RADICAL PROSTATECTOMY. <i>Journal of Pathology</i> , 1996, 178, 437-441.	4.5	174
41	Computed Tomography Radiomics Predicts HPV Status and Local Tumor Control After Definitive Radiochemotherapy in Head and Neck Squamous Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 921-928.	0.8	161
42	Renal Tumors. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1518-1531.	3.7	154
43	PDÅ€1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma. <i>International Journal of Cancer</i> , 2016, 139, 396-403.	5.1	151
44	SPOP Mutations in Prostate Cancer across Demographically Diverse Patient Cohorts. <i>Neoplasia</i> , 2014, 16, 14-W10.	5.3	145
45	Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors. <i>Nature Medicine</i> , 2017, 23, 1046-1054.	30.7	145
46	Loss of PBRM1 expression is associated with renal cell carcinoma progression. <i>International Journal of Cancer</i> , 2013, 132, E11-7.	5.1	139
47	pVHL and PTEN tumour suppressor proteins cooperatively suppress kidney cyst formation. <i>EMBO Journal</i> , 2008, 27, 1747-1757.	7.8	138
48	Tumor-associated macrophages subvert T-cell function and correlate with reduced survival in clear cell renal cell carcinoma. <i>Oncolmmunology</i> , 2013, 2, e23562.	4.6	138
49	Diagnostic and Prognostic Molecular Markers for Renal Cell Carcinoma: A Critical Appraisal of the Current State of Research and Clinical Applicability. <i>European Urology</i> , 2009, 55, 851-863.	1.9	132
50	Combined mutation of <i>Vhl</i> and <i>Trp53</i> causes renal cysts and tumours in mice. <i>EMBO Molecular Medicine</i> , 2013, 5, 949-964.	6.9	131
51	Hif-2Å± Promotes Degradation of Mammalian Peroxisomes by Selective Autophagy. <i>Cell Metabolism</i> , 2014, 20, 882-897.	16.2	131
52	ASPP2 controls epithelial plasticity and inhibits metastasis through Å²-catenin-dependent regulation of ÅZEB1. <i>Nature Cell Biology</i> , 2014, 16, 1092-1104.	10.3	129
53	HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy. , 2021, 9, e002071.		126
54	A Novel Tumor Grading Scheme for Chromophobe Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2010, 34, 1233-1240.	3.7	125

#	ARTICLE	IF	CITATIONS
55	The Value of In Vitro Diagnostic Testing in Medical Practice: A Status Report. PLoS ONE, 2016, 11, e0149856.	2.5	125
56	A Dual Role of Caspase-8 in Triggering and Sensing Proliferation-Associated DNA Damage, a Key Determinant of Liver Cancer Development. Cancer Cell, 2017, 32, 342-359.e10.	16.8	122
57	Microenvironmental control of breast cancer subtype elicited through paracrine platelet-derived growth factor-CC signaling. Nature Medicine, 2018, 24, 463-473.	30.7	120
58	Tumor Lymphangiogenesis and Metastasis to Lymph Nodes Induced by Cancer Cell Expression of Podoplanin. American Journal of Pathology, 2010, 177, 1004-1016.	3.8	117
59	An overview of renal cell cancer: Pathology and genetics. Seminars in Cancer Biology, 2013, 23, 3-9.	9.6	117
60	Comprehensive MicroRNA Expression Profiling Identifies Novel Markers in Follicular Variant of Papillary Thyroid Carcinoma. Thyroid, 2013, 23, 1383-1389.	4.5	117
61	Reassessing the Current UICC/AJCC TNM Staging for Renal Cell Carcinoma. European Urology, 2009, 56, 636-643.	1.9	114
62	Evaluation of the Clonal Relationship between Primary and Metastatic Renal Cell Carcinoma by Comparative Genomic Hybridization. American Journal of Pathology, 1999, 155, 267-274.	3.8	111
63	Genomic imbalances in the progression of endocrine pancreatic tumors. Genes Chromosomes and Cancer, 2001, 32, 364-372.	2.8	105
64	Sporadic clear cell renal cell carcinoma but not the papillary type is characterized by severely reduced frequency of primary cilia. Modern Pathology, 2009, 22, 31-36.	5.5	104
65	Combined mutation in Vhl, Trp53 and Rb1 causes clear cell renal cell carcinoma in mice. Nature Medicine, 2017, 23, 869-877.	30.7	101
66	MicroRNA Expression Array Identifies Novel Diagnostic Markers for Conventional and Oncocytic Follicular Thyroid Carcinomas. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1-E7.	3.6	99
67	Distance-Based Reconstruction of Tree Models for Oncogenesis. Journal of Computational Biology, 2000, 7, 789-803.	1.6	96
68	Expression of Epithelial Cell Adhesion Molecule (EpCam) in Renal Epithelial Tumors. American Journal of Surgical Pathology, 2005, 29, 83-88.	3.7	96
69	Mining Tissue Microarray Data to Uncover Combinations of Biomarker Expression Patterns that Improve Intermediate Staging and Grading of Clear Cell Renal Cell Cancer. Clinical Cancer Research, 2010, 16, 88-98.	7.0	94
70	SARS-CoV-2 leads to a small vessel endotheliitis in the heart. EBioMedicine, 2021, 63, 103182.	6.1	93
71	VHL Gene Mutations and Their Effects on Hypoxia Inducible Factor HIF1 α : Identification of Potential Driver and Passenger Mutations. Cancer Research, 2011, 71, 5500-5511.	0.9	92
72	Three-dimensional imaging mass cytometry for highly multiplexed molecular and cellular mapping of tissues and the tumor microenvironment. Nature Cancer, 2022, 3, 122-133.	13.2	92

#	ARTICLE	IF	CITATIONS
73	Collecting Duct Carcinoma Versus Renal Medullary Carcinoma. <i>American Journal of Surgical Pathology</i> , 2014, 38, 871-874.	3.7	90
74	Diagnostic criteria for oncocytic renal neoplasms: a survey of urologic pathologists. <i>Human Pathology</i> , 2017, 63, 149-156.	2.0	89
75	MicroRNA profile of poorly differentiated thyroid carcinomas: new diagnostic and prognostic insights. <i>Journal of Molecular Endocrinology</i> , 2014, 52, 181-189.	2.5	86
76	Antagonistic Cross-Regulation between Sox9 and Sox10 Controls an Anti-tumorigenic Program in Melanoma. <i>PLoS Genetics</i> , 2015, 11, e1004877.	3.5	85
77	Prognostic significance of epithelial-mesenchymal transition in malignant pleural mesothelioma. <i>European Journal of Cardio-thoracic Surgery</i> , 2010, 37, 566-572.	1.4	83
78	Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations of the Quality in Pathology Study. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1177-1189.	1.1	81
79	The IL-33/ST2 pathway contributes to intestinal tumorigenesis in humans and mice. <i>Oncolmmunology</i> , 2016, 5, e1062966.	4.6	80
80	Current Pathology Keys of Renal Cell Carcinoma. <i>European Urology</i> , 2011, 60, 634-643.	1.9	78
81	Discovery of new DNA amplification loci in prostate cancer by comparative genomic hybridization. <i>Prostate</i> , 2001, 46, 184-190.	2.3	76
82	Periostin is up-regulated in high grade and high stage prostate cancer. <i>BMC Cancer</i> , 2010, 10, 273.	2.6	74
83	The Tumor Profiler Study: integrated, multi-omic, functional tumor profiling for clinical decision support. <i>Cancer Cell</i> , 2021, 39, 288-293.	16.8	71
84	VHL-gene Deletion in Single Renal Tubular Epithelial Cells and Renal Tubular Cysts: Further Evidence for a Cyst-dependent Progression Pathway of Clear Cell Renal Carcinoma in von Hippel-Lindau Disease. <i>American Journal of Surgical Pathology</i> , 2010, 34, 806-815.	3.7	69
85	Tall cell papillary thyroid carcinoma: new diagnostic criteria and mutations in BRAF and TERT. <i>Endocrine-Related Cancer</i> , 2015, 22, 419-429.	3.1	68
86	Cystic Renal Tumors: New Entities and Novel Concepts. <i>Advances in Anatomic Pathology</i> , 2010, 17, 209-214.	4.3	67
87	Biomarker discovery for renal cancer stem cells. <i>Journal of Pathology: Clinical Research</i> , 2018, 4, 3-18.	3.0	67
88	Poorly Differentiated Thyroid Carcinomas. <i>American Journal of Surgical Pathology</i> , 2011, 35, 1866-1872.	3.7	66
89	Comparative genomic hybridization for genetic analysis of renal oncocytomas. <i>Genes Chromosomes and Cancer</i> , 1996, 17, 199-204.	2.8	65
90	Effect of MRE11 Loss on PARP-Inhibitor Sensitivity in Endometrial Cancer In Vitro. <i>PLoS ONE</i> , 2014, 9, e100041.	2.5	65

#	ARTICLE	IF	CITATIONS
91	Clear Cell Papillary Renal Cell Carcinoma and Renal Angiomyoadenomatous Tumor. American Journal of Surgical Pathology, 2015, 39, 889-901.	3.7	64
92	Electron microscopy of SARS-CoV-2: a challenging task – Authors' reply. Lancet, The, 2020, 395, e100.	13.7	64
93	Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome. Oncotarget, 2016, 7, 15018-15032.	1.8	62
94	Expression of histone deacetylases 1, 2 and 3 in urothelial bladder cancer. BMC Clinical Pathology, 2014, 14, 10.	1.8	61
95	Computed Tomography Perfusion Imaging of Renal Cell Carcinoma. Investigative Radiology, 2013, 48, 183-191.	6.2	59
96	Marked genetic similarities between hepatitis B virus-positive and hepatitis C virus-positive hepatocellular carcinomas. Journal of Pathology, 2000, 192, 307-312.	4.5	58
97	IGFBP2 and IGFBP3 Protein Expressions in Human Breast Cancer: Association with Hormonal Factors and Obesity. Clinical Cancer Research, 2010, 16, 1025-1032.	7.0	57
98	Diagnostic errors in the new millennium: a follow-up autopsy study. Modern Pathology, 2012, 25, 777-783.	5.5	56
99	FOCAL NEUROENDOCRINE DIFFERENTIATION LACKS PROGNOSTIC SIGNIFICANCE IN PROSTATE CORE NEEDLE BIOPSIES. Journal of Urology, 1998, 160, 406-410.	0.4	55
100	VHL mutations and dysregulation of pVHL- and PTEN-controlled pathways in multilocular cystic renal cell carcinoma. Modern Pathology, 2011, 24, 571-578.	5.5	55
101	pVHL/HIF-Regulated CD70 Expression Is Associated with Infiltration of CD27+ Lymphocytes and Increased Serum Levels of Soluble CD27 in Clear Cell Renal Cell Carcinoma. Clinical Cancer Research, 2015, 21, 889-898.	7.0	55
102	Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma. Neoplasia, 2019, 21, 247-256.	5.3	55
103	Defective Infiltration of Natural Killer Cells in MICA/B-Positive Renal Cell Carcinoma Involves β 2-Integrin-Mediated Interaction. Neoplasia, 2009, 11, 662-671.	5.3	54
104	Poorly differentiated oncocytic thyroid carcinoma – diagnostic implications and outcome. Histopathology, 2012, 60, 1045-1051.	2.9	53
105	EGF-r gene copy number changes in renal cell carcinoma detected by fluorescence in situ hybridization. , 1998, 184, 424-429.		52
106	Expression of the extracellular matrix protein periostin in liver tumours and bile duct carcinomas. Histopathology, 2010, 56, 600-606.	2.9	52
107	Chromosomal imbalances in small cell carcinomas of the urinary bladder. , 1999, 189, 230-235.		50
108	N-glycoprotein profiling of lung adenocarcinoma pleural effusions by shotgun proteomics. Cancer, 2008, 114, 124-133.	4.1	50

#	ARTICLE	IF	CITATIONS
109	Epidermal growth factor receptor protein expression and genomic alterations in renal cell carcinoma. <i>Cancer</i> , 2012, 118, 1268-1275.	4.1	48
110	A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience. <i>Oncologist</i> , 2021, 26, e769-e779.	3.7	48
111	Relevance of Periostin Splice Variants in Renal Cell Carcinoma. <i>American Journal of Pathology</i> , 2011, 179, 1513-1521.	3.8	47
112	Fullerenols and glucosamine fullerenes reduce infarct volume and cerebral inflammation after ischemic stroke in normotensive and hypertensive rats. <i>Experimental Neurology</i> , 2015, 265, 142-151.	4.1	47
113	Characterization of VHL missense mutations in sporadic clear cell renal cell carcinoma: hotspots, affected binding domains, functional impact on pVHL and therapeutic relevance. <i>BMC Cancer</i> , 2016, 16, 638.	2.6	47
114	Cytology smears as excellent starting material for next-generation sequencing-based molecular testing of patients with adenocarcinoma of the lung. <i>Cancer Cytopathology</i> , 2017, 125, 30-40.	2.4	47
115	Controversial issues in Gleason and International Society of Urological Pathology (ISUP) prostate cancer grading: proposed recommendations for international implementation. <i>Pathology</i> , 2019, 51, 463-473.	0.6	47
116	What's behind 68Ga-PSMA-11 uptake in primary prostate cancer PET? Investigation of histopathological parameters and immunohistochemical PSMA expression patterns. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 4042-4053.	6.4	47
117	CDKN2A Mutation Analysis, Protein Expression, and Deletion Mapping of Chromosome 9p in Conventional Clear-Cell Renal Carcinomas. <i>American Journal of Pathology</i> , 2001, 158, 593-601.	3.8	46
118	Extensive Histological Sampling following Focal Therapy of Clinically Significant Prostate Cancer with High Intensity Focused Ultrasound. <i>Journal of Urology</i> , 2019, 202, 717-724.	0.4	46
119	Cyclin D1 overexpression lacks prognostic significance in superficial urinary bladder cancer. <i>Journal of Pathology</i> , 1999, 188, 44-50.	4.5	45
120	Identification of Molecular Tumor Markers in Renal Cell Carcinomas with TFE3 Protein Expression by RNA Sequencing. <i>Neoplasia</i> , 2013, 15, 1231-1240.	5.3	45
121	MiR-99b-5p expression and response to tyrosine kinase inhibitor treatment in clear cell renal cell carcinoma patients. <i>Oncotarget</i> , 2016, 7, 78433-78447.	1.8	45
122	Automated immunofluorescence analysis defines microvessel area as a prognostic parameter in clear cell renal cell cancer. <i>Human Pathology</i> , 2007, 38, 1454-1462.	2.0	44
123	Loss of VHL and Hypoxia Provokes PAX2 Up-Regulation in Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2009, 15, 3297-3304.	7.0	44
124	Identification and Functional Characterization of pVHL-Dependent Cell Surface Proteins in Renal Cell Carcinoma. <i>Neoplasia</i> , 2012, 14, 535-IN17.	5.3	44
125	Cancer of unknown primary—Epidemiological trends and relevance of comprehensive genomic profiling. <i>Cancer Medicine</i> , 2018, 7, 4814-4824.	2.8	44
126	Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer. <i>Oncotarget</i> , 2018, 9, 10284-10293.	1.8	44

#	ARTICLE	IF	CITATIONS
127	Anti-neuroblastoma antibody chCE7 binds to an isoform of L1-CAM present in renal carcinoma cells. , 1999, 83, 401-408.		43
128	Association of cytokeratin 7 and 19 expression with genomic stability and favorable prognosis in clear cell renal cell cancer. International Journal of Cancer, 2008, 123, 569-576.	5.1	43
129	Multi-institutional re-evaluation of prognostic factors in chromophobe renal cell carcinoma: proposal of a novel two-tiered grading scheme. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 409-418.	2.8	42
130	Effect of the integrin inhibitor cilengitide on TGF-beta signaling.. Journal of Clinical Oncology, 2012, 30, 2055-2055.	1.6	42
131	Comparative genomic hybridization reveals frequent chromosome 13q and 4q losses in renal carcinomas with sarcomatoid transformation. , 1998, 185, 382-388.		41
132	Detailed simulation of cancer exome sequencing data reveals differences and common limitations of variant callers. BMC Bioinformatics, 2017, 18, 8.	2.6	40
133	Loss of SLC45A3 protein (prostein) expression in prostate cancer is associated with <i>SLC45A3</i> gene rearrangement and an unfavorable clinical course. International Journal of Cancer, 2013, 132, 807-812.	5.1	39
134	Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design. Oncologist, 2021, 26, e394-e402.	3.7	39
135	WHO 2022 landscape of papillary and chromophobe renal cell carcinoma. Histopathology, 2022, 81, 426-438.	2.9	39
136	Mutations in the tyrosine kinase domain of the EGFR gene are rare in synovial sarcoma. Modern Pathology, 2006, 19, 541-547.	5.5	38
137	Handling and reporting of nephrectomy specimens for adult renal tumours: a survey by the European Network of Urothology. Journal of Clinical Pathology, 2012, 65, 106-113.	2.0	37
138	Heterogeneity of chromosome 17 and erbB-2 gene copy number in primary and metastatic bladder cancer. Cytometry, 1995, 21, 40-46.	1.8	36
139	Similar lymphocytic infiltration pattern in primary breast cancer and their corresponding distant metastases. Oncoimmunology, 2016, 5, e1153208.	4.6	36
140	Prominent Oncogenic Roles of EVI1 in Breast Carcinoma. Cancer Research, 2017, 77, 2148-2160.	0.9	36
141	Lack of MRE11-RAD50-NBS1 (MRN) complex detection occurs frequently in low-grade epithelial ovarian cancer. BMC Cancer, 2017, 17, 44.	2.6	36
142	Relevance of Nuclear and Cytoplasmic von Hippel Lindau Protein Expression for Renal Carcinoma Progression. American Journal of Pathology, 2003, 163, 1013-1020.	3.8	34
143	Connexin 43 expression predicts poor progression-free survival in patients with non-muscle invasive urothelial bladder cancer. Journal of Clinical Pathology, 2015, 68, 819-824.	2.0	34
144	Tracing Clonal Dynamics Reveals that Two- and Three-dimensional Patient-derived Cell Models Capture Tumor Heterogeneity of Clear Cell Renal Cell Carcinoma. European Urology Focus, 2021, 7, 152-162.	3.1	34

#	ARTICLE	IF	CITATIONS
145	Towards a new WHO classification of renal cell tumor: what the clinician needs to know—a narrative review. <i>Translational Andrology and Urology</i> , 2021, 10, 1506-1520.	1.4	34
146	The Diabetes Gene JAZF1 Is Essential for the Homeostatic Control of Ribosome Biogenesis and Function in Metabolic Stress. <i>Cell Reports</i> , 2020, 32, 107846.	6.4	33
147	IL-8 and CXCR1 expression is associated with cancer stem cell-like properties of clear cell renal cancer. <i>Journal of Pathology</i> , 2019, 248, 377-389.	4.5	32
148	Preoperative assessment of CD44-mediated depth of invasion as predictor of occult metastases in early oral squamous cell carcinoma. <i>Head and Neck</i> , 2019, 41, 950-958.	2.0	32
149	An introduction to the WHO 5th edition 2022 classification of testicular tumours. <i>Histopathology</i> , 2022, 81, 459-466.	2.9	32
150	Diagnostic and prognostic implications of the PAX8-PPAR β translocation in thyroid carcinomas—a TMA-based study of 226 cases. <i>Histopathology</i> , 2013, 63, 234-241.	2.9	31
151	Chromophobe renal cell carcinoma: current and controversial issues. <i>Pathology</i> , 2021, 53, 101-108.	0.6	31
152	Mirna Expression in Bladder Cancer and Their Potential Role in Clinical Practice. <i>Current Drug Metabolism</i> , 2017, 18, 712-722.	1.2	31
153	Interleukin-33 in human gliomas: Expression and prognostic significance. <i>Oncology Letters</i> , 2016, 12, 445-452.	1.8	29
154	Intraductal carcinoma of the prostate is an aggressive form of invasive carcinoma and should be graded. <i>Pathology</i> , 2020, 52, 192-196.	0.6	29
155	Higher prevalence of pulmonary macrothrombi in SARS-CoV-2 than in influenza A: autopsy results from Spanish flu 1918/1919 in Switzerland to Coronavirus disease 2019. <i>Journal of Pathology: Clinical Research</i> , 2021, 7, 135-143.	3.0	29
156	Image-based computational quantification and visualization of genetic alterations and tumour heterogeneity. <i>Scientific Reports</i> , 2016, 6, 24146.	3.3	28
157	Detecting circulating tumor DNA in renal cancer: An open challenge. <i>Experimental and Molecular Pathology</i> , 2017, 102, 255-261.	2.1	28
158	Classic Chromophobe Renal Cell Carcinoma Incur a Larger Number of Chromosomal Losses than Seen in the Eosinophilic Subtype. <i>Cancers</i> , 2019, 11, 1492.	3.7	28
159	YAP1-TFE3-fused hemangioendothelioma: a multi-institutional clinicopathologic study of 24 genetically-confirmed cases. <i>Modern Pathology</i> , 2021, 34, 2211-2221.	5.5	28
160	Oncotargets in Different Renal Cancer Subtypes. <i>Current Drug Targets</i> , 2015, 16, 125-135.	2.1	28
161	Altered expression of mdm-2 and its association with p53 protein status, tumor-cell-proliferation rate and prognosis in cervical neoplasia. , 1997, 74, 421-425.		27
162	Biomarkers in renal cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014, 464, 359-365.	2.8	27

#	ARTICLE	IF	CITATIONS
163	Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?. PLoS ONE, 2015, 10, e0139438.	2.5	27
164	Clear cell renal cell carcinoma with wild-type von Hippel-Lindau gene: a non-existent or new tumour entity?. Histopathology, 2019, 74, 60-67.	2.9	27
165	CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo. Journal of Clinical Investigation, 2020, 130, 2435-2450.	8.2	27
166	Dynamic prostate cancer transcriptome analysis delineates the trajectory to disease progression. Nature Communications, 2021, 12, 7033.	12.8	27
167	Synthetic lethality between BRCA1 deficiency and poly(ADP-ribose) polymerase inhibition is modulated by processing of endogenous oxidative DNA damage. Nucleic Acids Research, 2019, 47, 9132-9143.	14.5	26
168	Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer. Nature Communications, 2021, 12, 734.	12.8	26
169	Integrative genome-wide expression profiling identifies three distinct molecular subgroups of renal cell carcinoma with different patient outcome. BMC Cancer, 2012, 12, 310.	2.6	25
170	NGS-pipe: a flexible, easily extendable and highly configurable framework for NGS analysis. Bioinformatics, 2018, 34, 107-108.	4.1	25
171	Autopsy-Based Pulmonary and Vascular Pathology: Pulmonary Endotheliitis and Multi-Organ Involvement in COVID-19 Associated Deaths. Respiration, 2022, 101, 155-165.	2.6	25
172	Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future Perspectives. Current Drug Metabolism, 2017, 18, 700-711.	1.2	25
173	Cancer Sample Biobanking at the Next Level: Combining Tissue With Living Cell Repositories to Promote Precision Medicine. Frontiers in Cell and Developmental Biology, 2019, 7, 246.	3.7	24
174	hKPNA2 is overexpressed in human and mouse endometrial cancers and promotes cellular proliferation. Journal of Pathology, 2014, 234, 239-252.	4.5	23
175	Clonal Hematopoiesis in Hospitalized Elderly Patients With COVID-19. HemaSphere, 2020, 4, e453.	2.7	23
176	Differential PD-1/LAG-3 expression and immune phenotypes in metastatic sites of breast cancer. Breast Cancer Research, 2021, 23, 4.	5.0	23
177	External Validation and Comparison of Prostate Cancer Risk Calculators Incorporating Multiparametric Magnetic Resonance Imaging for Prediction of Clinically Significant Prostate Cancer. Journal of Urology, 2020, 203, 719-726.	0.4	23
178	Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumours. British Journal of Cancer, 2022, 126, 1140-1144.	6.4	23
179	Concomitant Detection of HER2 Protein and Gene Alterations by Immunohistochemistry (IHC) and Silver Enhanced In Situ Hybridization (SISH) Identifies HER2 Positive Breast Cancer with and without Gene Amplification. PLoS ONE, 2014, 9, e105961.	2.5	22
180	Cancer testis antigen expression in testicular germ cell tumorigenesis. Modern Pathology, 2014, 27, 899-905.	5.5	22

#	ARTICLE	IF	CITATIONS
181	MAGI3- <i>AKT3</i> fusion in breast cancer amended. <i>Nature</i> , 2015, 520, E11-E12.	27.8	22
182	Characterization of the 19q12 amplification including CCNE1 and URI in different epithelial ovarian cancer subtypes. <i>Experimental and Molecular Pathology</i> , 2015, 98, 47-54.	2.1	22
183	Challenges in Pathologic Staging of Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1253-1261.	3.7	22
184	Histological and molecular characterization of TFEB-rearranged renal cell carcinomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 625-631.	2.8	22
185	A curated collection of tissue microarray images and clinical outcome data of prostate cancer patients. <i>Scientific Data</i> , 2017, 4, 170014.	5.3	21
186	<i>STRN-ALK</i> Rearranged Malignant Peritoneal Mesothelioma With Dramatic Response Following Ceritinib Treatment. <i>JCO Precision Oncology</i> , 2019, 3, 1-6.	3.0	21
187	Loss of CDKN1A mRNA and Protein Expression Are Independent Predictors of Poor Outcome in Chromophobe Renal Cell Carcinoma Patients. <i>Cancers</i> , 2020, 12, 465.	3.7	21
188	Genetic progression of renal cell carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2002, 441, 320-327.	2.8	20
189	Granular necrosis: a distinctive form of cell death in malignant tumours. <i>Pathology</i> , 2020, 52, 507-514.	0.6	20
190	The leading role of pathology in assessing the somatic molecular alterations of cancer: Position Paper of the European Society of Pathology. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 476, 491-497.	2.8	20
191	Expanding the clinicopathological spectrum of succinate dehydrogenase-deficient renal cell carcinoma with a focus on variant morphologies: a study of 62 new tumors in 59 patients. <i>Modern Pathology</i> , 2022, 35, 836-849.	5.5	20
192	DNA Aneuploidy, S-phase fraction, nuclear p53 positivity, and survival in non-small-cell lung carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 1997, 431, 173-179.	2.8	19
193	Surfaceome of classical Hodgkin and non-Hodgkin lymphoma. <i>Proteomics - Clinical Applications</i> , 2015, 9, 661-670.	1.6	19
194	Interleukin-33 Expression Indicates a Favorable Prognosis in Malignant Salivary Gland Tumors. <i>International Journal of Surgical Pathology</i> , 2016, 24, 394-400.	0.8	19
195	Novel morphological and genetic features of fumarate hydratase deficient renal cell carcinoma in <i>HLRCC</i> syndrome patients with a tailored therapeutic approach. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 611-619.	2.8	19
196	Value of postmortem studies in deceased neonatal and pediatric intensive care unit patients. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 217-223.	2.8	18
197	Similarities and Differences in the 2019 ISUP and GUPS Recommendations on Prostate Cancer Grading: A Guide for Practicing Pathologists. <i>Advances in Anatomic Pathology</i> , 2021, 28, 1-7.	4.3	18
198	Long-Term Persisting SARS-CoV-2 RNA and Pathological Findings: Lessons Learnt From a Series of 35 COVID-19 Autopsies. <i>Frontiers in Medicine</i> , 2022, 9, 778489.	2.6	18

#	ARTICLE	IF	CITATIONS
199	Flurocholine Transport Mediated by the Organic Cation Transporter 2 (OCT2, SLC22A2): Implication for Imaging of Kidney Tumors. <i>Drug Metabolism and Disposition</i> , 2018, 46, 1129-1136.	3.3	17
200	Scavenger receptor BI promotes cytoplasmic accumulation of lipoproteins in clear-cell renal cell carcinoma. <i>Journal of Lipid Research</i> , 2018, 59, 2188-2201.	4.2	16
201	Allele Loss and Reduced Expression of CYCLOPS Genes is a Characteristic Feature of Chromophobe Renal Cell Carcinoma. <i>Translational Oncology</i> , 2019, 12, 1131-1137.	3.7	16
202	Specific immune cell and lymphatic vessel signatures identified by image analysis in renal cancer. <i>Modern Pathology</i> , 2019, 32, 1042-1052.	5.5	16
203	Liquid Biopsies in Renal Cell Carcinoma—Recent Advances and Promising New Technologies for the Early Detection of Metastatic Disease. <i>Frontiers in Oncology</i> , 2020, 10, 582843.	2.8	16
204	The Role of Frozen Section Examination During Inguinal Exploration in Men with Inconclusive Testicular Tumors: A Systematic Review and Meta-analysis. <i>European Urology Focus</i> , 2021, 7, 1400-1402.	3.1	16
205	Detection of <i>CCNE1/URI</i> (19q12) amplification by <i>in situ</i> hybridisation is common in high grade and type II endometrial cancer. <i>Oncotarget</i> , 2017, 8, 14794-14805.	1.8	16
206	The Morphological Spectrum of Papillary Renal Cell Carcinoma and Prevalence of Provisional/Emerging Renal Tumor Entities with Papillary Growth. <i>Biomedicines</i> , 2021, 9, 1418.	3.2	16
207	Amplification and expression of EGFR and ERBB2 in Wilms tumor. <i>Cancer Genetics and Cytogenetics</i> , 2009, 194, 88-95.	1.0	15
208	An Aggressive Hypoxia Related Subpopulation of Melanoma Cells is TRP-2 Negative. <i>Translational Oncology</i> , 2014, 7, 206-212.	3.7	15
209	Functional characterization of BC039389-GATM and KLK4-KRSP1 chimeric read-through transcripts which are up-regulated in renal cell cancer. <i>BMC Genomics</i> , 2015, 16, 247.	2.8	15
210	Morphoproteomic Characterization of Lung Squamous Cell Carcinoma Fragmentation, a Histological Marker of Increased Tumor Invasiveness. <i>Cancer Research</i> , 2017, 77, 2585-2593.	0.9	15
211	Human Streptococcal Necrotizing Fasciitis Histopathology Mirrored in a Murine Model. <i>American Journal of Pathology</i> , 2018, 188, 1517-1523.	3.8	15
212	Machine learning with autophagy-related proteins for discriminating renal cell carcinoma subtypes. <i>Scientific Reports</i> , 2020, 10, 720.	3.3	15
213	Establishing standardized immune phenotyping of metastatic melanoma by digital pathology. <i>Laboratory Investigation</i> , 2021, 101, 1561-1570.	3.7	15
214	Negative LC3b immunoreactivity in cancer cells is an independent prognostic predictor of prostate cancer specific death. <i>Oncotarget</i> , 2017, 8, 31765-31774.	1.8	15
215	miR-30c-2-3p and miR-30a-3p: New Pieces of the Jigsaw Puzzle in HIF2 α Regulation. <i>Cancer Discovery</i> , 2014, 4, 22-24.	9.4	14
216	Eight autopsy cases of melanoma brain metastases showing angiotropism and pericytic mimicry. Implications for extravascular migratory metastasis. <i>Journal of Cutaneous Pathology</i> , 2019, 46, 570-578.	1.3	14

#	ARTICLE	IF	CITATIONS
217	Data set for the reporting of carcinoma of renal tubular origin: recommendations from the International Collaboration on Cancer Reporting (<scp>ICCR</scp>). <i>Histopathology</i> , 2019, 74, 377-390.	2.9	14
218	Molecular characterization and diagnostic criteria of renal cell carcinoma with emphasis on liquid biopsies. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 141-150.	3.1	14
219	Complete remission of pulmonary metastases of Bellini duct carcinoma with cisplatin, gemcitabine and bevacizumab: a case report. <i>American Journal of Case Reports</i> , 2012, 13, 1-2.	0.8	14
220	Cutaneous Melanoma with Brain Metastasis: Report of 193 Patients with New Observations. <i>PLoS ONE</i> , 2016, 11, e0156115.	2.5	13
221	Tracking the origin of simultaneous endometrial and ovarian cancer by next-generation sequencing â€” a case report. <i>BMC Cancer</i> , 2017, 17, 66.	2.6	13
222	Targeted next-generation-sequencing for reliable detection of targetable rearrangements in lung adenocarcinomaâ€”a single center retrospective study. <i>Pathology Research and Practice</i> , 2018, 214, 572-578.	2.3	13
223	HNF1Î² is a sensitive and specific novel marker for yolk sac tumor: a tissue microarray analysis of 601 testicular germ cell tumors. <i>Modern Pathology</i> , 2020, 33, 2354-2360.	5.5	13
224	Alterations in homologous recombination repair genes in prostate cancer brain metastases. <i>Nature Communications</i> , 2022, 13, 2400.	12.8	13
225	Diagnostic Accuracy of Quantitative and Qualitative Phase-Contrast Imaging for the ex Vivo Characterization of Human Coronary Atherosclerotic Plaques. <i>Radiology</i> , 2015, 277, 64-72.	7.3	12
226	PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: The Role of PD-L1 Assay. <i>Current Drug Targets</i> , 2020, 21, 1664-1671.	2.1	12
227	The protein tyrosine phosphatase receptor type J is regulated by the <scp>pVHLâ€™HIF</scp> axis in clear cell renal cell carcinoma. <i>Journal of Pathology</i> , 2013, 229, 525-534.	4.5	11
228	Multi-laboratory proficiency testing of clinical cancer genomic profiling by next-generation sequencing. <i>Pathology Research and Practice</i> , 2018, 214, 957-963.	2.3	11
229	Automated Assessment of Î²-Cell Area and Density per Islet and Patient Using TMEM27 and BACE2 Immunofluorescence Staining in Human Pancreatic Î²-Cells. <i>PLoS ONE</i> , 2014, 9, e98932.	2.5	11
230	<i>VHL</i> missense mutations in the p53 binding domain show different effects on p53 signaling and HIFÎ± degradation in clear cell renal cell carcinoma. <i>Oncotarget</i> , 2017, 8, 10199-10212.	1.8	11
231	Papillary renal cell carcinoma: current and controversial issues. <i>Current Opinion in Urology</i> , 2022, 32, 344-351.	1.8	11
232	MiRNAs Are Involved in Tall Cell Morphology in Papillary Thyroid Carcinoma. <i>Cancers</i> , 2019, 11, 885.	3.7	10
233	Spatial Distribution of Private Gene Mutations in Clear Cell Renal Cell Carcinoma. <i>Cancers</i> , 2021, 13, 2163.	3.7	10
234	Oxygen supply maps for hypoxic microenvironment visualization in prostate cancer. <i>Journal of Pathology Informatics</i> , 2016, 7, 3.	1.7	10

#	ARTICLE	IF	CITATIONS
235	Downregulation of Autophagy-Related Proteins 1, 5, and 16 in Testicular Germ Cell Tumors Parallels Lowered LC3B and Elevated p62 Levels, Suggesting Reduced Basal Autophagy. <i>Frontiers in Oncology</i> , 2018, 8, 366.	2.8	9
236	Takotsubo Syndrome in Coronavirus Disease 2019. <i>American Journal of Cardiology</i> , 2021, 138, 118-120.	1.6	9
237	Weakly Supervised Cell Nuclei Detection and Segmentation on Tissue Microarrays of Renal Clear Cell Carcinoma. <i>Lecture Notes in Computer Science</i> , 2008, , 173-182.	1.3	9
238	Importance of excision repair cross-complementation group 1 and ribonucleotide reductase M1 as prognostic biomarkers in malignant pleural mesothelioma treated with platinum-based induction chemotherapy followed by surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2015, 149, 1539-1547.e1.	0.8	8
239	Interaction of tumor cells with infiltrating lymphocytes via CD70 and CD27 in clear cell renal cell carcinoma. <i>Oncolmmunology</i> , 2015, 4, e1049805.	4.6	8
240	Mass Spectrometry Imaging Differentiates Chromophobe Renal Cell Carcinoma and Renal Oncocytoma with High Accuracy. <i>Journal of Cancer</i> , 2020, 11, 6081-6089.	2.5	8
241	MALDI Mass Spectrometry Imagingâ€”Prognostic Pathways and Metabolites for Renal Cell Carcinomas. <i>Cancers</i> , 2022, 14, 1763.	3.7	8
242	Eosinophilic solid and cystic renal cell carcinoma and renal cell carcinomas with <i>TFEB</i> alterations: a comparative study. <i>Histopathology</i> , 2022, 81, 32-43.	2.9	8
243	Morphological clues to the appropriate recognition of hereditary renal neoplasms. <i>Seminars in Diagnostic Pathology</i> , 2018, 35, 184-192.	1.5	7
244	Cytoplasmic ADP-ribosylation levels correlate with markers of patient outcome in distinct human cancers. <i>Modern Pathology</i> , 2021, 34, 1468-1477.	5.5	7
245	Circulating Tumor Cells: A Reliable Biomarker for Prostate Cancer Treatment Assessment?. <i>Current Drug Metabolism</i> , 2017, 18, 692-699.	1.2	7
246	The synergism of spatial metabolomics and morphometry improves machine learningâ€”based renal tumour subtype classification. <i>Clinical and Translational Medicine</i> , 2022, 12, e666.	4.0	7
247	Towards a national strategy for digital pathology in Switzerland. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 481, 647-652.	2.8	7
248	Clinical impact of prostate biopsy undergrading in an academic and community setting. <i>World Journal of Urology</i> , 2016, 34, 1481-1490.	2.2	6
249	Computer-Based Intensity Measurement Assists Pathologists in Scoring Phosphatase and Tensin Homolog Immunohistochemistry â€” Clinical Associations in NSCLC Patients of the European Thoracic Oncology Platform Lungscape Cohort. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1851-1863.	1.1	6
250	Intraductal carcinoma of the prostate is not a diagnostic entity. <i>Histopathology</i> , 2021, 78, 342-344.	2.9	6
251	SAMHD1 mutations in mantle cell lymphoma are recurrent and confer in vitro resistance to nucleoside analogues. <i>Leukemia Research</i> , 2021, 107, 106608.	0.8	6
252	Genomic profiling of carcinomas of unknown primary (CUP) to support clinical decisions.. <i>Journal of Clinical Oncology</i> , 2018, 36, e24162-e24162.	1.6	6

#	ARTICLE	IF	CITATIONS
253	Statistical tests for intra-tumour clonal co-occurrence and exclusivity. PLoS Computational Biology, 2021, 17, e1009036.	3.2	6
254	Morphological spectrum and molecular features of somatic malignant transformation in germ cell tumours. Histopathology, 2022, 81, 84-98.	2.9	6
255	Modelling of a genetically diverse evolution of Systemic Mastocytosis with Chronic Myelomonocytic Leukemia (SM-CMML) by Next Generation Sequencing. Experimental Hematology and Oncology, 2014, 3, 18.	5.0	5
256	Somatic BRCA1 mutations in clinically sporadic breast cancer with medullary histological features. Journal of Cancer Research and Clinical Oncology, 2018, 144, 865-874.	2.5	5
257	Advancing synoptic cancer reports beyond English: the University of Bern/PathoLink approach. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 473, 655-656.	2.8	5
258	Chromophobe Renal Cell Carcinoma Aggressiveness and Immuno-oncology Therapy: How to Distinguish the Good One from the Bad One. European Urology Oncology, 2021, 4, 331-333.	5.4	5
259	Renal cell carcinoma pathology in 2021: â€œnew need for renal cancer immune profilingâ€™. Current Opinion in Urology, 2021, 31, 228-235.	1.8	5
260	Randomized Tree Ensembles for Object Detection in Computational Pathology. Lecture Notes in Computer Science, 2009, , 367-378.	1.3	5
261	A novel 5x multiplex immunohistochemical staining reveals PSMA as a helpful marker in prostate cancer with low p504s expression.. Pathology Research and Practice, 2021, 228, 153667.	2.3	5
262	Updates in Grading of Renal Cell Carcinomas Beyond Clear Cell Renal Cell Carcinoma and Papillary Renal Cell Carcinoma. Advances in Anatomic Pathology, 2022, 29, 117-130.	4.3	5
263	Genomic alterations in renal tumours: what have we learned in the era of comparative genomic hybridisation?. Pathology, 2004, 36, 51-57.	0.6	4
264	Board examination for anatomical pathology in Switzerland: two intense days to verify professional competence. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 461, 87-92.	2.8	4
265	CXCL12 expression is an adverse predictor for disease recurrence in patients with metastatic non-seminomatous testicular germ cell tumors. BMC Cancer, 2019, 19, 802.	2.6	4
266	Dataset for the reporting of renal biopsy for tumour: recommendations from the International Collaboration on Cancer Reporting (ICCR). Journal of Clinical Pathology, 2019, 72, 573-578.	2.0	4
267	Re: Multi-institutional Re-evaluation of Prognostic Factors in Chromophobe Renal Cell Carcinoma: Proposal of a Novel Two-tiered Grading Scheme. European Urology, 2020, 78, 114-116.	1.9	4
268	Novel RGAG1-BCOR gene fusion revealed in a somatic soft tissue sarcoma with a long follow-up. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 1107-1114.	2.8	4
269	Analysis of BRAF and NRAS mutation status in advanced melanoma patients treated with anti-CTLA-4 antibodies: Association with overall survival?. Journal of Clinical Oncology, 2013, 31, 9025-9025.	1.6	4
270	Discretization of Gene Expression Data Unmasks Molecular Subgroups Recurring in Different Human Cancer Types. PLoS ONE, 2016, 11, e0161514.	2.5	4

#	ARTICLE	IF	CITATIONS
271	Probing Isoform Switching Events in Various Cancer Types: Lessons From Pan-Cancer Studies. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 726902.	3.5	4
272	Variants and Variations in Epithelial Renal Cell Tumors in Adults: The Pathologist's Point of View. <i>European Urology Supplements</i> , 2017, 16, 232-240.	0.1	3
273	The expression of the cancer testis antigen MAGE A4: A favorable prognostic biomarker in salivary gland carcinomas related to low tumor grading. <i>Laryngoscope Investigative Otolaryngology</i> , 2018, 3, 182-190.	1.5	3
274	ALK-rearranged renal cell carcinomaâ€”different morphological faces of a rare tumor. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 477, 759-760.	2.8	3
275	Integrated Analysis Of Immunotherapy Treated Clear Cell Renal Cell Carcinomas: An Exploratory Study. <i>Journal of Immunotherapy</i> , 2022, 45, 35-42.	2.4	3
276	Comparative genomic hybridization for genetic analysis of renal oncocytomas. <i>Genes Chromosomes and Cancer</i> , 1996, 17, 199-204.	2.8	3
277	L1-CAM is commonly expressed in testicular germ cell tumours. <i>Journal of Clinical Pathology</i> , 2016, 69, 460-462.	2.0	3
278	Urinary Biomarkers for Prostate Cancer. <i>Current Drug Metabolism</i> , 2017, 18, 723-726.	1.2	3
279	Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study. <i>Journal of Personalized Medicine</i> , 2022, 12, 727.	2.5	3
280	Modified Immunoscore Improves Prediction of Survival Outcomes in Patients Undergoing Radical Cystectomy for Bladder Cancerâ€”A Retrospective Digital Pathology Study. <i>Diagnostics</i> , 2022, 12, 1360.	2.6	3
281	Immunohistochemical detection of CD3 in T-cell lymphomas: superior sensitivity of rabbit monoclonal 2CV6 antibody compared to mouse monoclonal F7A-2A-38 antibody. <i>Journal of Histotechnology</i> , 2012, 35, 175-179.	0.5	2
282	Clinical Trials for Specific Renal Cancer Subtypesâ€”The Time Will Come!. <i>European Urology Supplements</i> , 2017, 16, 241-252.	0.1	2
283	Re: Svetlana Avulova, John C. Cheville, Christine M. Lohse, et al. Grading Chromophobe Renal Cell Carcinoma: Evidence for a Four-tiered Classification Incorporating Coagulative Tumor Necrosis. <i>Eur Urol</i> 2021;79:225â€”31. <i>European Urology</i> , 2021, 80, e17-e18.	1.9	2
284	Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma. <i>Cancer</i> , 2000, 89, 604-614.	4.1	2
285	Reply to JÃ©rÃ©me Verine, Christophe Leboeuf and Philippe Ratajczak's Letter to the Editor re: Jimsgene Sanjmyatav, Sven Hauke, Mieczyslaw Gajda, et al. Establishment of a Multicolour Fluorescence In Situ Hybridisation-based Assay for Subtyping of Renal Cell Tumours. <i>Eur Urol</i> 2013;64:689â€”91. <i>European Urology</i> , 2014, 65, e71-e72.	1.9	1
286	Chromosomal aberrations of cancerâ€”testis antigens in myeloma patients. <i>Hematological Oncology</i> , 2015, 33, 159-163.	1.7	1
287	The Pros and Comms of Gene Sequencing. <i>Biomedicine Hub</i> , 2017, 2, 1-5.	1.2	1
288	Frequent expression of PD-L1 in testicular germ cell tumors.. <i>Journal of Clinical Oncology</i> , 2015, 33, 379-379.	1.6	1

#	ARTICLE	IF	CITATIONS
289	The HLA Ligand Atlas: A novel immuno-oncology resource for T-cell antigen discovery.. Journal of Clinical Oncology, 2020, 38, 3128-3128.	1.6	1
290	Immunohistochemical Expression Pattern of Theragnostic Targets SSTR2 and PSMA in Endolymphatic Sac Tumors: A Single Institution Case Series. Head and Neck Pathology, 2022, , .	2.6	1
291	CD10 expression in 325 testicular germ cell tumours. Journal of Clinical Pathology, 2015, 68, 400-403.	2.0	0
292	The maturation stage of tumoral tertiary lymphoid structures to predict recurrence risk in localized colorectal cancer.. Journal of Clinical Oncology, 2017, 35, e15083-e15083.	1.6	0
293	Glioblastoma in the era of bevacizumab: An epidemiological study in the Canton of Zurich, Switzerland, 2010-2014.. Journal of Clinical Oncology, 2018, 36, e14062-e14062.	1.6	0
294	Frequency, molecular characteristics, and therapeutic targeting of ROS1 oncogenic fusions in colorectal cancer.. Journal of Clinical Oncology, 2022, 40, 160-160.	1.6	0